ReviewSensors (Basel, Switzerland)2026
Biophysical Sensing Tools in Drug Discovery: Integrating Kinetics, Thermodynamics, Cellular Target Engagement and Structure.
Review in Sensors (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biophysical sensing technologies have become central to modern drug discovery because they enable direct, quantitative characterization of ligand-target interactions. In contrast to conventional biochemical and cellular assays that infer binding from downstream functional responses, biophysical methods detect interaction events through measurable physical changes such as refractive index, heat, fluorescence, mass, or protein stability. This review surveys the major classes of biophysical sensors used in drug discovery, including surface-based optical methods, calorimetry, solution-state spectroscopic techniques, mass spectrometry-based approaches, and cellular target engagement assays. For each modality, we outline the measurement principle, the key parameters obtained, and its value across hit identification, hit validation, lead optimization, and mechanism-of-action studies. We also emphasize the growing importance of combining orthogonal methods to improve confidence in binding data, resolve assay artifacts, and strengthen early decision-making. Finally, we discuss how biophysical measurements are increasingly integrated with structural biology and computational analysis to support more predictive and mechanism-driven discovery workflows. Collectively, these technologies provide a richer and more reliable understanding of molecular recognition and thereby improve the progression of drug candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.